Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2566 to 2580 of 7687 results

  1. LY3209590 for treating type 2 diabetes in people on daily insulin injections [ID6499]

    Awaiting development [GID-TA11644] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Digital platforms for community based self-management of mild to moderate osteoarthritis and joint pain: Early value assessment

    Awaiting development [GID-HTE10057] Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  3. Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]

    In development [GID-TA11386] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]

    In development [GID-TA10979] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Delgocitinib for treating moderate to severe chronic hand eczema ID6408

    In development [GID-TA11506] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Cladribine for treating relapsing multiple sclerosis [ID6263]

    In development [GID-TA11293] Expected publication date: 05 February 2025

    Technology appraisal guidance
    In development

  7. Leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over [ID6130]

    In development [GID-HST10059] Expected publication date: 05 March 2025

    Highly specialised technologies guidance
    In development

  8. Electrically stimulated intravesical therapy for interstitial cystitis or overactive bladder in adults

    In development [GID-IPG10362] Expected publication date: 09 January 2025

    Interventional procedures guidance
    In development

  9. Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer ID6339

    In development [GID-TA11432] Expected publication date: 02 July 2025

    Technology appraisal guidance
    In development

  10. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development [GID-TA11220] Expected publication date: 05 February 2025

    Technology appraisal guidance
    In development

  11. Epcoritamab for treating relapsed or refractory follicular lymphoma ID6338

    In development [GID-TA11385] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Obesity: prevention and lifestyle management (QS update)

    In development [GID-QS10184] Expected publication date: TBC

    Quality standard
    In development

  13. Obesity: clinical assessment and management (QS update)

    In development [GID-QS10183] Expected publication date: TBC

    Quality standard
    In development

  14. Cardiovascular risk assessment and lipid modification

    In development [GID-QS10187] Expected publication date: 23 July 2025

    Quality standard
    In development

  15. Biomarker tests to help diagnose preterm labour in women with intact membranes (DG33)

    Evidence-based recommendations on biomarker tests to help diagnose preterm labour in women with intact membranes. The tests are Actim Partus, PartoSure and the Rapid fetal fibronectin (fFN) 10Q Cassette Kit (at thresholds other than 50 nanograms/millilitre)

    Diagnostics guidance
    Published
    4 July 2018
    View recommendations

    Sections for DG33